SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Feb 6, 2019
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Feb. 6, 2019 · CIK: 0000946644 · Accession: 0001493152-19-001476
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229051
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, DC 20549 Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-1 (SEC File No. 333-229051) Filed with the Commission on December 27, 2018
Dear Sir or Madam:
On behalf of Hemispherx Biopharma, Inc. (the “Company”), we file herewith Amendment No. 1 to the above referenced registration statement. It contains all of the material terms of the rights offering.
As the Company’s financial statements go stale end of day on February 14, 2019, we anticipate requesting acceleration to that date.
If you have any questions, please contact me as soon as possible.
Very
truly yours,
/s/
Richard Feiner
Show Raw Text
CORRESP
1
filename1.htm
SILVERMAN
SHIN & BYRNE PLLC
New
Jersey
Wall
Street Plaza
19
Engle Street
22nd
Floor
Tenafly,
NJ 07670
88
Pine Street
(201)
567-4969
NEW
YORK, NY 10005
212.779.8600
Facsimile:
212.779.8858
February
6, 2019
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20549
Re:
Hemispherx
Biopharma, Inc.
Registration
Statement on Form S-1 (SEC File No. 333-229051)
Filed
with the Commission on December 27, 2018
Dear
Sir or Madam:
On
behalf of Hemispherx Biopharma, Inc. (the “Company”), we file herewith Amendment No. 1 to the above referenced registration
statement. It contains all of the material terms of the rights offering.
As
the Company’s financial statements go stale end of day on February 14, 2019, we anticipate requesting acceleration to that
date.
If
you have any questions, please contact me as soon as possible.
Very
truly yours,
/s/
Richard Feiner
Richard
Feiner
cc:
Hemispherx Biopharma, Inc.